Megan M Herr

28PUBLICATIONS
205CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Oct 23, 2026
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.

|Sep 24, 2026
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

|Jul 02, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Mar 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga, Myra Robinson, James A Davis

|Feb 02, 2026
Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models.

Mackenzie M Lieberman, Jason H Tong, Nkechi U Odukwe

Pageof 5

Frequent Collaborators

16 joint publications

James A Davis

15 joint publications

Surbhi Sidana

14 joint publications

Krina Patel

14 joint publications

Jack Khouri